Zimmer Biomet Holdings, Inc.(ZBH) Stock Research - Grey Stern Research
Loading...

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis

$112.15 (1.36%)

ZBH Financial Performance


Use the table below to view Zimmer Biomet Holdings, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $112.15 -
52 Week Low $97.69 -
52 Week High $133.90 -
Market Cap $22.3 Billion 6/16
Gross Margin 0% 16/16
Profit Margin 0% 10/16
EBITDA margin -100% 16/16
Q3 - 2024 Revenue $0 16/16
Q3 - 2024 Earnings $0 10/16
Q3 - 2024 Free Cash Flow $0 13/16
Trailing 4 Quarters Revenue $5.7 Billion 6/16
Trailing 4 Quarters Earnings $664.3 Million 6/16
Quarterly Earnings Growth 0% 9/16
Annual Earnings Growth 36% 5/16
Quarterly Revenue Growth -100% 15/16
Annual Revenue Growth 4% 10/16
Cash On Hand $525.5 Million 5/16
Short Term Debt $863.0 Million 5/16
Long Term Debt $5.3 Billion 4/16

Zimmer Biomet Holdings, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Zimmer Biomet Holdings, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 33.61 5/16
PS 3.95 7/16
PB 1.55 14/16
PC 42.48 5/16
Liabilities to Equity 0.48 11/16
ROA 0.03 8/16
ROE 0.05 9/16
Current Ratio 3.08 5/16
Quick Ratio 0.08 10/16
Long Term Debt to Equity 0.37 9/16
Debt to Equity 0.43 9/16
Burn Rate -1.00 15/16
Cash to Cap 0.02 12/16
CCR 13/16
EV to EBITDA -1.00 12/16
EV to Revenue -1.00 16/16

Company Details

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

CEO: Mr. Bryan Hanson

Website: https://www.zimmerbiomet.com

Address: 345 E Main St Warsaw Indiana, INDIANA

Exchange: New York Stock Exchange

Industry: Medical Devices

Zimmer Biomet Holdings, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Zimmer Biomet Holdings, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $149.1 Billion
Abbott Laboratories ABT $227.8 Billion
Medtronic plc MDT $114.1 Billion
Glaukos Corporation GKOS $5.9 Billion
Edwards Lifesciences Corporation EW $41.9 Billion
Stryker Corporation SYK $140.2 Billion
Bruker Corporation BRKR $6.6 Billion
NuVasive, Inc. NUVA $2.1 Billion
Bio-Rad Laboratories, Inc. BIO $6.9 Billion
Integer Holdings Corporation ITGR $4.0 Billion
CONMED Corporation CNMD $1.8 Billion
Surmodics, Inc. SRDX $437.6 Million
Orthofix Medical Inc. OFIX $630.6 Million
Pulmonx Corporation LUNG $270.2 Million
CVRx, Inc. CVRX $321.0 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ZBH Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 0 $0
Q3 2024 $ 1.8 Billion $249.1 Million
Q2 2024 $ 1.9 Billion $242.8 Million
Q1 2024 $ 1.9 Billion $172.4 Million
Q4 2023 $ 183.7 Million $0
Q3 2023 $ 1.8 Billion $162.8 Million
Q2 2023 $ 1.9 Billion $209.6 Million
Q1 2023 $ 1.8 Billion $232.5 Million

View All

ZBH Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $525.5 Million $21.4 Billion $6.2 Billion $14.4 Billion
Q3 2024 $569.0 Million $21.7 Billion $6.6 Billion $12.4 Billion
Q2 2024 $420.1 Million $21.5 Billion $5.8 Billion $12.7 Billion
Q1 2024 $393.0 Million $21.5 Billion $5.8 Billion $12.6 Billion
Q4 2023 $415.8 Million $21.5 Billion $5.8 Billion $14.7 Billion
Q3 2023 $292.1 Million $21.2 Billion $5.5 Billion $12.5 Billion
Q2 2023 $319.8 Million $21.3 Billion $5.7 Billion $12.4 Billion
Q1 2023 $330.2 Million $21.2 Billion $5.8 Billion $12.2 Billion

View All

ZBH Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $368.6 Million -$27.1 Million $148.9 Million
Q2 2024 $264.0 Million -$105.4 Million $27.1 Million
Q1 2024 $78.4 Million -$149.6 Million -$22.8 Million
Q4 2023 $446.7 Million -$141.7 Million $123.7 Million
Q3 2023 $0 $0 $0
Q2 2023 $177.3 Million -$170.6 Million -$10.4 Million
Q1 2023 $261.0 Million -$46.7 Million -$45.5 Million
Q4 2022 $180.8 Million -$63.4 Million -$169.7 Million

View All